Wynveris SA
Wnt inhibition without prohibitive toxicity
Wynveris develops first-in-class receptor-selective Wnt inhibitors. Unlike prior broad approaches, our compounds inhibit only the receptor a tumor depends on. Healthy tissue can rely on other receptors. This selectivity has the potential to hit the tumor hard without the prohibitive toxicity of previously failed treatments.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
No news
No milestones
No Jobs
No videos and documents
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Wynveris SA
Wnt inhibition without prohibitive toxicity
Website:
wynveris.com
Headquarter:
Geneva
Foundation Date:
April 2026
Technology:
- Biotech
Sectors:
- Biotech
- Drug discovery
- Small molecule drugs
Support received
